Abstract

Peri-operative cisplatin-based chemotherapy is the standard of care for potentially operable OGC1. OGC is associated with an increased risk of TE2, which may be further increased by potentially thrombogenic cisplatin chemotherapy. Current international guidelines do not recommend prophylactic anticoagulation in the ambulatory setting3. The aim of this retrospective single-centre study was to quantify the frequency and consequences of TE during neo-adjuvant chemotherapy in pts with OGC.